MFN as a stress test for pharma price governance
External price referencing is re-entering the US debate, but its implications extend far beyond policy mechanics. Most Favored Nation (MFN) proposals can directly link US and ex-US drug prices, creating new cross-market risks that directly affect US revenue. For pharma leaders, it can serve as a catalyst to stress test global pricing governance across list, net, and realized metrics.
MFN policy: The current state of play
Most Favored Nation pricing seeks to link US drug prices to those in other developed countries, using both list and net price benchmarks. Even as design specifics and legal and political uncertainty remain, US drug pricing is increasingly exposed to international price levels and net price dynamics. Recent policy discussions signal renewed momentum around external price referencing for US drug cost containment, increasing the strategic importance of global pricing interdependencies.
